2E. M. Leslie, R. G. Deeley,S. P. Cole. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense[J]. Toxicol Appl Pharmacoll, 2005, 204 (3) :216-237.
3E. Choong, M. Dobrinas, P. A. Carrupt, et al. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution[J]. Expert Opin Drug Metab Toxicoll, 2010, 6 (8) :953-965.
4J. Ferte. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane[J]. Eur J Biocheml, 2000, 267 (2) :277-294.
5P. Kwan and M. J. Brodie. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy[J]. Epilepsial, 2005, 46 (2) :224-235.
6Y. Romsicki and F. J. Sharom. The ATPase and ATP-binding functions of P-glycoprotein—modulation by interaction with defined phospholipids[J]. Eur J Biocheml, 1998, 256 (1) :170-178.
8L. Su, P. Jenardhanan, D. D. Mruk, et al. Role of P-glycoprotein at the blood-testis barrier on adjudin distribution in the testis: a revisit of recent data[J]. Adv Exp Med Bioll, 2012, 763 :318-333.
9A. E. Hudson and H. C. Hemmings, Jr. Are anaesthetics toxic to the brain?[J]. Br J Anaesthl, 2011, 107 (1) :30-37.
10J. J. Harrington, G. Van Bokkelen, R. W. Mays, et al. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes[J]. Nat Genetl, 1997, 15 (4) :345-355.
